Self-Reported Adverse Events Associated With Antimalarial Chemoprophylaxis in Peace Corps Volunteers

American Journal of Preventive Medicine

Volumn 33, Issue 3, 2007, Pages 194-199

  Korhonen, Christine ^a   Peterson, Katia ^b   Bruder, Catherine ^c   Jung, Paul ^a  

^a Peace Corps   (United States)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHLOROQUINE; DOXYCYCLINE; MEFLOQUINE;

ABDOMINAL PAIN; ADULT; ANXIETY; ARTICLE; AUTUMN; CHEMOPROPHYLAXIS; DEPRESSION; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DREAM; DRUG INDUCED HEADACHE; ENDEMIC DISEASE; FEMALE; GASTROINTESTINAL SYMPTOM; HEALTH SURVEY; HOSPITALIZATION; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALARIA; MALE; MYCOSIS; NAUSEA; NEUROLOGIC DISEASE; PHOTOSENSITIVITY; PRURITUS; SELF REPORT; SIDE EFFECT; SKIN DISEASE; UNSTEADINESS; VAGINA DISEASE; VISUAL DISORDER; VOLUNTEER; VOMITING; WEAKNESS;

ADULT; ANTIMALARIALS; DOXYCYCLINE; FEMALE; GASTROINTESTINAL DISEASES; GOVERNMENT AGENCIES; HOSPITALIZATION; HUMANS; MALARIA; MALE; MEFLOQUINE; NERVOUS SYSTEM DISEASES; PATIENT COMPLIANCE; QUESTIONNAIRES; SEVERITY OF ILLNESS INDEX; SKIN DISEASES; TIME FACTORS; TRAVEL; VOLUNTARY WORKERS;

EID: 34548439878     PISSN: 07493797     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amepre.2007.04.029     Document Type: Article

References (14)

1. Centers for Disease Control and Prevention. Frequently Asked Questions About Malaria. August 13, 2004. Available at http://www.cdc.gov/malaria/faq.htm. Accessed February 26, 2007.
2. World Tourism Organisation. "Another Record Year for Tourism." Press Release. January 29, 2007. Available at http://www.world-tourism.org/newsroom/Releases/2007/january/recordyear.htm. Accessed February 26, 2007.
3. Chen L.H., Wilson M.E., and Schlagenhauf P. Prevention of malaria in long-term travelers. JAMA 296 (2006) 2234-2244
4. Cave W., Pandey P., Osrin D., et al. Chemoprophylaxis use and the risk of malaria in travelers to Nepal. J Trav Med 10 (2003) 100-105
5. Hoebe C., de Munter J., and Thijs C. Adverse effects and compliance with mefloquine or proguanil antimalarial chemoprophylaxis. Euro J Clin Pharm 52 (1997) 269-275
6. Petersen E., Ronne T., Ronn A., et al. Reported side effects to chloroquine, chloroquine plus proguanil, and mefloquine as chemoprophylaxis against malaria in Danish travelers. J Trav Med 7 (2000) 79-84
7. Carme B., Peguet C., and Nevez G. Compliance with and tolerance of mefloquine and chloroquine + proguanil malaria chemoprophylaxis in French short-term travellers to sub-Saharan Africa. Trop Med Int Hlth 2 (1997) 953-956
8. Schlagenhauf P., Tschop A., Johnson R., et al. Tolerability of malaria chemoprophylaxis in non-immune travelers to sub-Saharan Africa: multicentre, randomized, double blind, four-arm study. BMJ 327 (2003) 1078-1083
9. Wells T.S., Smith T.C., Smith B., et al. Mefloquine use and hospitalizations among US service members, 2002-2004. Am J Trop Med Hyg 74 (2006) 744-749
10. Hopperus Buma A.P., van Thiel P.P., Lobel H.O., et al. Long-term malaria chemoprophylaxis with mefloquine in Dutch marines in Cambodia. J Infect Dis 173 (1996) 1506-1509
11. Lobel H.O., Miani M., Eng T., Bernard K.W., Hightower A.W., and Campbell C.C. Long-term malaria prophylaxis with weekly mefloquine. Lancet 341 (1993) 848-851
12. Centers for Disease Control and Prevention. Health Information for International Travel 2005-2006 (2005), U.S. Department of Health and Human Services, Public Health Service, Atlanta
13. Barrett P.J., Emmins P.D., Clarke P.D., and Bradley D.J. Comparison of adverse events associated with use of mefloquine and combination of chloroquine and proguanil as antimalarial prophylaxis: postal and telephone survey of travellers. BMJ 313 (1996) 525-528
14. Bernard K.W., Graitcer P.L., van der Vlugt T., et al. Epidemiological surveillance in Peace Corps volunteers: a model for monitoring health in temporary residents of developing countries. Int J Epidemiol 18 (1989) 220-226